Annals of Emergency Medicine
Volume 54, Issue 6 , Pages 811-817.e3 , December 2009

Levosimendan as a Rescue Drug in Experimental Propranolol-Induced Myocardial Depression: A Randomized Study

  • Heli Leppikangas, MD

      Affiliations

    • Department of Anaesthesia, Tampere University Hospital, Tampere, Finland
    • ,
  • Esko Ruokonen, MD, PhD

      Affiliations

    • Department of Intensive Care, Kuopio University Hospital, Kuopio, Finland
    • ,
  • Juha Rutanen, MD, PhD

      Affiliations

    • Department of Intensive Care, Kuopio University Hospital, Kuopio, Finland
    • ,
  • Vesa Kiviniemi, PhLic

      Affiliations

    • IT Centre, University of Kuopio, Kuopio, Finland
    • ,
  • Leena Lindgren, MD, PhD

      Affiliations

    • Department of Anaesthesia, Tampere University Hospital, Tampere, Finland
    • ,
  • Jouni Kurola, MD, PhD

      Affiliations

    • Department of Intensive Care, Kuopio University Hospital, Kuopio, Finland
    • Corresponding Author InformationAddress for correspondence: Kurola Jouni, MD, PhD, Department of Intensive Care, Kuopio University Hospital, PO Box 1777, 70211 Kuopio, Finland; 358-40-5677189, fax 358-17-173443

Received 23 December 2008 ,Revised 30 April 2009 ,Accepted 24 June 2009.

References 

  1. Bronstein AC, Spyker DA, Cantilena LR, et al. American Association of Poison Control Centers 2007 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th annual report. Clin Toxicol (Phila). 2008;46:927–1057
  2. DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel and beta-blocker toxicity. Toxicol Rev. 2004;23:223–238
  3. Newton CRH, Delgado JH, Gomez H. Calcium and beta receptor antagonist overdose: a review and update of pharmacological principles and management. Semin Respir Crit Care Med. 2002;23:19–25
  4. Sandroni C, Cavallaro F, Addario C, et al. Successful treatment with enoximone for severe poisoning with atenolol and verapamil: a case report. Acta Anesth Scand. 2004;48:790–792
  5. Sainz R, Berestrand W, Williams W, et al. Atenolol-induced cardiovascular collapse treated with haemodialysis. Crit Care Med. 1991;19:116–118
  6. Pfaender M, Casetti PG, Azzolini M, et al. Successful treatment of massive atenolol and nifedipine overdose with CVVHDF. Minerva Anestesiol. 2008;74:97–100
  7. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27:1859–1866
  8. Sorsa T, Heikkinen S, Abbott MB, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem. 2001;276:9337–9343
  9. Givertz MM, Andreou C, Conrad CH, et al. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation frequency relationships. Circulation. 2007;115:1218–1224
  10. Sonntag S, Sundberg S, Lehtonen LA, et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43:2177–2182
  11. Pagel PS, Harkin CP, Hettrick DA, et al. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology. 1994;81:974–987
  12. Pataricza J, Hohn J, Petri A, et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol. 2000;52:213–217
  13. Haikala H, Nissinen E, Etemadzadeh E, et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol. 1995;25:794–801
  14. Morelli A, De Castro S, Teboul J-L, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005;31:638–644
  15. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141–2147
  16. Lochner A, Colesky F, Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic response of the myocardium. Cardiovasc Drugs Ther. 2000;14:271–281
  17. Packer M, Carver JR, Rodeheffer RJ, et al. Effects of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468–1475
  18. Yokoshiki H, Katsube Y, Sunagawa M, et al. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249–259
  19. Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111:1504–1509
  20. Slawsky MT, Colucci WS, Gottlieb SS, et al. ; for the Study Investigators (Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure). Circulation. 2000;102:2222–2227
  21. Yokoshiki H, Sperelakis N. Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther. 2003;17:111–113
  22. Oh YJ, Lee JH, Kim JY, et al. The haemodynamic effects of propranolol and atenolol medication on dobutamine infusion in patients with coronary artery obstructive disease. J Int Med Res. 2005;33:329–336
  23. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet. 2002;360:196–202

 Provide feedback on this article at the journal's Web site, www.annemergmed.com.

 Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. Financial support provided by Orion Pharma Inc.

 Supervising editor: Richard C. Dart, MD, PhD

 Author contributions: HL, ER, LL, and JK designed the study and obtained research funding. HL, JR, and JK performed the study. HL, VK, and JK performed statistical analysis. HL, ER, LL, and JK prepared the article. JK takes responsibility for the paper as a whole.

 Reprints not available from the authors.

 Publication date: Available online September 19, 2009.

PII: S0196-0644(09)01143-3

doi: 10.1016/j.annemergmed.2009.06.512

Annals of Emergency Medicine
Volume 54, Issue 6 , Pages 811-817.e3 , December 2009

Article Tools

* Image Usage & Resolution